Myeloperoxidase levels predict accelerated progression of coronary atherosclerosis in diabetic patients: Insights from intravascular ultrasound

Atherosclerosis

Volumn 232, Issue 2, 2014, Pages 377-383

  Kataoka, Yu ^a   Shao, Mingyuan ^a   Wolski, Kathy ^a   Uno, Kiyoko ^a   Puri, Rishi ^a   Murat Tuzcu, E ^a   Hazen, Stanley L ^a,b   Nissen, Steven E ^a   Nicholls, Stephen J ^a,c  

^a Clevel and Clinic ^*  (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

^c SOUTH AUSTRALIAN HEALTH AND MEDICAL RESEARCH INSTITUTE   (Australia)

Author keywords

Atheroma progression; Coronary atherosclerosis; Diabetes mellitus; Intravascular ultrasound; Myeloperoxidase

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C REACTIVE PROTEIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MYELOPEROXIDASE;

ADULT; ANGIOCARDIOGRAPHY; ARTICLE; ATHEROMA; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY RISK; DIABETIC PATIENT; DISEASE ASSOCIATION; DISEASE COURSE; DRUG MEGADOSE; FEMALE; HUMAN; INTRAVASCULAR ULTRASOUND; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PRIORITY JOURNAL; SEX DIFFERENCE; SMOKING;

ATHEROMA PROGRESSION; CAD; CORONARY ARTERY DISEASE; CORONARY ATHEROSCLEROSIS; DIABETES MELLITUS; DM; EEM; EXTERNAL ELASTIC MEMBRANE; HDL; HIGH SENSITIVITY C-REACTIVE PROTEIN; HIGH-DENSITY LIPOPROTEIN; HSCRP; INTRAVASCULAR ULTRASOUND; IVUS; LDL; LOW-DENSITY LIPOPROTEIN; MPO; MYELOPEROXIDASE; PAV; PERCENT ATHEROMA VOLUME;

AGED; CHOLESTEROL, LDL; CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; DIABETES COMPLICATIONS; DIABETES MELLITUS; DISEASE PROGRESSION; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INFLAMMATION; MALE; MIDDLE AGED; PEROXIDASE; PLAQUE, ATHEROSCLEROTIC; ULTRASONOGRAPHY, INTERVENTIONAL;

EID: 84892840896     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2013.11.075     Document Type: Article

References (39)

1. Huxley R., Barzi F., Woodward M. Excess risk of fatal coronary heart disease associated with diabetes in men and women: meta-analysis of 37 prospective cohort studies. BMJ 2006, 332:73-78.
2. Ho J.E., Paultre F., Mosca L., Women's Pooling Project Is diabetes mellitus a cardiovascular disease risk equivalent for fatal stroke in women? Data from the Women's Pooling Project. Stroke 2003, 34:2812-2816.
3. Nicholls S.J., Tuzcu E.M., Kalidindi S., et al. Effect of diabetes on progression of coronary atherosclerosis and arterial remodeling: a pooled analysis of 5 intravascular ultrasound trials. JAm Coll Cardiol 2008, 52:255-262.
4. Stamler J., Vaccaro O., Neaton J.D., Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993, 16:434-444.
5. Duncan B.B., Schmidt M.I., Pankow J.S., Atherosclerosis Risk in Communities Study, et al. Low-grade systemic inflammation and the development of type 2 diabetes: the atherosclerosis risk in communities study. Diabetes 2003, 52:1799-1805.
6. Haffner S.M. Insulin resistance, inflammation, and the prediabetic state. Am J Cardiol 2003, 92:18J-26J.
7. Moreno P.R., Fuster V. New aspects in the pathogenesis of diabetic atherosclerosis. JAm Coll Cardiol 2004, 44:2293-2300.
8. Koh K.K., Han S.H., Quon M.J. Inflammatory markers and the metabolic syndrome: insights from therapeutic interventions. JAm Coll Cardiol 2005, 46:1978-1985.
9. Moreno P.R., Murcia A.M., Palacios I.F., et al. Coronary composition and macrophage infiltration in atherectomy specimens from patients with diabetes mellitus. Circulation 2000, 102:2180-2184.
10. Burke A.P., Kolodgie F.D., Zieske A., et al. Morphologic findings of coronary atherosclerotic plaques in diabetics: a postmortem study. Arterioscler Thromb Vasc Biol 2004, 24:1266-1271.
11. Mita T., Watada H., Uchino H., et al. Association of C-reactive protein with early-stage carotid atherosclerosis in Japanese patients with early-stage type 2 diabetes mellitus. Endocr J 2006, 53:693-698.
12. Sander D., Schulze-Horn C., Bickel H., Gnahn H., Bartels E., Conrad B. Combined effects of hemoglobin A1c and C-reactive protein on the progression of subclinical carotid atherosclerosis: the INVADE study. Stroke 2006, 37:351-357.
13. Nicholls S.J., Hazen S.L. Myeloperoxidase and cardiovascular disease. Arterioscler Thromb Vasc Biol 2005, 25:1102-1111.
14. Nicholls S.J., Hazen S.L. Myeloperoxidase, modified lipoproteins, and atherogenesis. JLipid Res 2009, 50(Suppl.):S346-S351.
15. Klebanoff S.J. Oxygen metabolism and the toxic properties of phagocytes. Ann Intern Med 1980, 93:480-489.
16. Rausch P.G., Pryzwansky K.B., Spitznagel J.K. Immunocytochemicalidentification of azurophilic and specific granule markers in the giant granules of Chediak-Higashi neutrophils. NEngl J Med 1978, 298:693-698.
17. Baldus S., Eiserich J.P., Brennan M.L., Jackson R.M., Alexander C.B., Freeman B.A. Spatial mapping of pulmonary and vascular nitrotyrosinereveals the pivotal role of myeloperoxidase as a catalyst for tyrosine nitration in inflammatory diseases. Free Radic Biol Med 2002, 33:1010.
18. Baldus S., Eiserich J.P., Mani A., et al. Endothelial transcytosis of myeloperoxidase confers specificity to vascular ECM proteins as targets of tyrosine nitration. JClin Invest 2001, 108:1759-1770.
19. Hazen S.L., Heinecke J.W. 3-Chlorotyrosine, a specific marker of myeloperoxidase-catalyzed oxidation, is markedly elevated in low density lipoprotein isolated from human atherosclerotic intima. JClin Invest 1997, 99:2075-2081.
20. Podrez E.A., Schmitt D., Hoff H.F., Hazen S.L. Myeloperoxidase-generated reactive nitrogen species convert LDL into an atherogenic form invitro. JClin Invest 1999, 103:1547-1560.
21. Zheng L., Nukuna B., Brennan M.L., et al. Apolipoprotein A-1 is a selective target for myeloperoxidase-catalyzed oxidation and functional impairment in subject with cardiovascular disease. JClin Invest 2004, 114:529-541.
22. Shao B., Oda M.N., Bergt C., et al. Myeloperoxidase impairs ABCA1-dependent cholesterol efflux through methionine oxidation and site-specific tyrosine chlorination of apolipoprotein A-I. JBiol Chem 2006, 281:9001-9004.
23. Undurti A., Huang Y., Lupica J.A., Smith J.D., DiDonato J.A., Hazen S.L. Modification of high density lipoprotein by myeloperoxidase generates a pro-inflammatory particle. JBiol Chem 2009, 284:30825-30835.
24. Eiserich J.P., Baldus S., Brennan M.L., et al. Myeloperoxidase, a leukocyte-derived vascular NO oxidase. Science 2002, 296:2391-2394.
25. Vita J.A., Brennan M.L., Gokce N., et al. Serum myeloperoxidase levels independently predict endothelial dysfunction in humans. Circulation 2004, 110:1134-1139.
26. Abu-Soud H.M., Hazen S.L. Nitric oxide modulates the catalytic activity of myeloperoxidase. JBiol Chem 2000, 275:5425-5430.
27. Sorrentino S.A., Besler C., Rohrer L., et al. Endothelial-vasoprotective effects of high-density lipoprotein are impaired in patients with type 2 diabetes mellitus but are improved after extended-release niacin therapy. Circulation 2010, 121:110-122.
28. Nicholls S.J., Tuzcu E.M., Sipahi I., Schoenhagen P., Nissen S.E. Intravascular ultrasound in cardiovascular medicine. Circulation 2006, 114:e55-e59.
29. Nissen S.E., Tuzcu E.M., Schoenhagen P., REVERSAL Investigators, et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA 2004, 291:1071-1080.
30. Nissen S.E., Tuzcu E.M., Libby P., CAMELOT Investigators, et al. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. JAMA 2004, 292:2217-2225.
31. Nissen S.E., Tuzcu E.M., Brewer H.B., ACAT Intravascular Atherosclerosis Treatment Evaluation (ACTIVATE) Investigators, et al. Effect of ACAT inhibition on the progression of coronary atherosclerosis. NEngl J Med 2006, 354:1253-1263.
32. Nicholls S.J., Tang W.H., Brennan D., et al. Risk prediction with serial myeloperoxidase monitoring in patients with acute chest pain. Clin Chem 2011, 57:1762-1770.
33. Brennan M.L., Penn M.S., Van Lente F., et al. Prognostic value of myeloperoxidase in patients with chest pain. NEngl J Med 2003, 349:1595-1604.
34. Baldus S., Heeschen C., Meinertz T., CAPTURE Investigators, et al. Myeloperoxidase serum levels predict risk in patients with acute coronary syndromes. Circulation 2003, 108:1440-1445.
35. Meuwese M.C., Stroes E.S., Hazen S.L., et al. Serum myeloperoxidase levels are associated with the future risk of coronary artery disease in apparently healthy individuals: the EPIC-Norfolk Prospective Population Study. JAm Coll Cardiol 2007, 50:159-165.
36. Zhang R., Brennan M.L., Fu X., et al. Association between myeloperoxidase levels and risk of coronary artery disease. JAMA 2001, 286:2136-2142.
37. Heslop C.L., Frohlich J.J., Hill J.S. Myeloperoxidase and C-reactive protein have combined utility for long-term prediction of cardiovascular mortality after coronary angiography. JAm Coll Cardiol 2010, 55:1102-1109.
38. Zhang C., Yang J., Jennings L.K. Leukocyte-derived myeloperoxidase amplifies high-glucose-induced endothelial dysfunction through interaction with high-glucose-stimulated, vascular non-leukocyte-derived reactive oxygen species. Diabetes 2004, 53:2950-2959.
39. Nicholls S.J., Hsu A., Wolski K., et al. Intravascular ultrasound-derived measures of coronary atherosclerotic plaque burden and clinical outcome. JAm Coll Cardiol 2010, 55:2399-2407.